Ascletis Pharma-B (01672.HK) has submitted two Investigational New Drug (IND) applications to the U.S. FDA for the treatment of obesity: ASC36, a monthly injection of the peptide amylin receptor agonist, and ASC36_35, a monthly injection combining ASC36 and the peptide GLP-1R/GIPR agonist ASC35. – Sohu.com

Full Article Content

Ascletis Pharma-B (01672. HK) announced that it has recently submitted two Investigational New Drug (IND) applications to the U. S. Food and Drug Administration (FDA): one for ASC36, a next-generation peptide amylin receptor agonist administered once monthly to quarterly, and the other for ASC36_35 FDC, a once-monthly injectable combination of ASC36 and the peptide GLP-1R/GIPR agonist ASC35, for the treatment of obesity. Investment banks have generally given the stock a "buy" rating, with one investment bank issuing a "buy" rating in the past 90 days. The average target price over the past 90 days is HK$24.63. A recent research report from Orient Securities gave Ascletis Pharma-B a "buy" rating with a target price of HK$24.63. Ascletis Pharma-B has a market capitalization of HK$11.983 billion in Hong Kong, ranking 13th in the Biopharmaceuticals II industry. Key indicators are shown in the table below. The above information is compiled by Securities Star based on publicly available information and is for reference only, not investment advice.